Skip to main content
. 2010 Mar 3;30(9):3276–3286. doi: 10.1523/JNEUROSCI.4634-09.2010

Figure 8.

Figure 8.

Previous exposure to cAMP activity inhibitor rp-cAMPS attenuated withdrawal symptoms to intra-VTA naloxone in morphine-treated WT mice. A, Global withdrawal score after intra-VTA NLX infusion (500 ng/0.5 μl) in drug-naive/untreated WT mice (NLX), in mice treated chronically with morphine (10 mg/kg, s.c., twice per day for 5 d; Chronic Morphine + NLX) or in mice treated with chronic morphine (10 mg/kg, s.c., twice per day for 5 d) that received the cAMP activity blocker rp-cAMPS (50 ng/0.5 μl) in the VTA 30 min before intra-VTA naloxone (Chronic Morphine + rp-cAMPS + NLX). Global withdrawal score was significantly higher after chronic morphine treatment and was attenuated by rp-cAMPS preexposure [NLX (n = 9) vs Chronic Morphine + NLX (n = 6) vs Chronic Morphine + rp-cAMPS + NLX (n = 6)]. B–E, Quantification of behavioral signs of intra-VTA NLX-precipitated morphine withdrawal and the effects of rp-cAMPS preexposure. B, Tremors were significantly attenuated after rp-cAMPS preexposure. C, Rears were significantly attenuated after rp-cAMPS preexposure. D, Wet-dog shakes were reduced after rp-cAMPS preexposure. E, Grooming behavior was similar after rp-cAMPS preexposure. *p < 0.05, **p < 0.01, ***p < 0.001.